Skip to main content
Top
Published in: Infection 6/2006

Open Access 01-12-2006 | Clinical and Epidemiological Study

Surveillance of Antimicrobial Use and Antimicrobial Resistance in German Intensive Care Units (SARI): A Summary of the Data from 2001 through 2004

Authors: E. Meyer, F. Schwab, P. Gastmeier, H. Rueden, F. D. Daschner

Published in: Infection | Issue 6/2006

Login to get access

Abstract

Objective:

To report the experience gained over 4 years in working with the German SARI project (Surveillance of Antimicrobial Use and Antimicrobial Resistance in Intensive Care Units), and to compare SARI with data from the Swedish STRAMA and the US AUR surveillance system.

Methods:

Prospective unit and laboratory based surveillance was carried out in 40 German ICUs from 2001 through 2004. WHO 2004 definitions of defined daily doses (DDD) per 1,000 patient days (pd) were used to express antimicrobial consumption (AD). Apart from the proportion of resistant isolates (RP), the incidence density of resistant isolates (RD) was calculated on the basis of the number of resistant isolates per 1,000 pd. To determine the changes over time, the Wilcoxon signed rank test for paired samples was used.

Results:

From 1/2001 through 12/2004, 40 ICUs provided data on 53,399 isolates, a total of 789,569 DDD and 597,592 pd. Total AD ranged from 427 to 2,798, with the median being 1,351. There was no statistically significant change in total antimicrobial use, but a statistically significant decrease was observed in the use of aminoglycosides. RD was highest for MRSA with 4.4 resistant isolates/1,000 pd followed by imipenem resistant Pseudomonas aeruginosa with 1.7 resistant isolates/1,000 pd. The corresponding RPs were 21.5% and 23.2%. Over the 4-year period (2001–2004), significant increases were seen in the RDs of third generation cephalosporin and ciprofloxacin resistant Escherichia coli. In 2004, the mean RD reached 0.28 and 1.41, respectively. In comparison, the RP of selected pathogens was highest in the US ICUs and lowest in Swedish ICUs, with the exception of imipenem resistant P. aeruginosa.

Conclusion:

Antibiotic consumption remained stable over a period of 4 years, (the mean being 1,321 DDD/1,000 pd). The same applied to the situation regarding resistance in Staphylococcus aureus, enterococci and P. aeruginosa. For most pathogens the RP was higher in SARI ICUs than in Swedish ICUs, but lower than in US ICUs.
Literature
1.
go back to reference Fridkin SK: Increasing prevalence of antimicrobial resistance in intensive care units. Crit Care Med 2001; 29: N64–N68.CrossRefPubMed Fridkin SK: Increasing prevalence of antimicrobial resistance in intensive care units. Crit Care Med 2001; 29: N64–N68.CrossRefPubMed
2.
go back to reference Kollef MH, Fraser VJ: Antibiotic resistance in the intensive care unit. Ann Intern Med 2001; 134: 298–314.PubMed Kollef MH, Fraser VJ: Antibiotic resistance in the intensive care unit. Ann Intern Med 2001; 134: 298–314.PubMed
3.
go back to reference Harbarth S, Samore MH: Antimicrobial resistance determinants and future control. Emerg Infect Dis 2005; 11: 794–811.PubMed Harbarth S, Samore MH: Antimicrobial resistance determinants and future control. Emerg Infect Dis 2005; 11: 794–811.PubMed
4.
go back to reference Council recommendation on the prudent use of antimicrobial agents in human medicine. Official Journal of the European Communities (2002/77/EC), L 34-13-L 34/16, 2002. Council recommendation on the prudent use of antimicrobial agents in human medicine. Official Journal of the European Communities (2002/77/EC), L 34-13-L 34/16, 2002.
5.
go back to reference World Health Organisation: WHO global strategy for containment of antimicrobial resistance. 2001 WHO/CDS/CSR/ DRS/2001.2. World Health Organisation: WHO global strategy for containment of antimicrobial resistance. 2001 WHO/CDS/CSR/ DRS/2001.2.
6.
go back to reference Fridkin SK, Lawton R, Edwards JR, Tenover FC, McGowan JE Jr, Gaynes RP: Monitoring antimicrobial use and resistance: comparison with a national benchmark on reducing vancomycin use and vancomycin-resistant enterococci. Emerg Infect Dis 2002; 8: 702–707.PubMed Fridkin SK, Lawton R, Edwards JR, Tenover FC, McGowan JE Jr, Gaynes RP: Monitoring antimicrobial use and resistance: comparison with a national benchmark on reducing vancomycin use and vancomycin-resistant enterococci. Emerg Infect Dis 2002; 8: 702–707.PubMed
7.
go back to reference Hanberger H, Erlandsson M, Burman LG, Cars O, Gill H, Lindgren S, Lennart N, Olsson-Liljequist B, Walther SM: High antibiotic susceptibility among bacterial pathogens in Swedish ICUs. Report from a nation-wide surveillance program using TA90 as a novel index of susceptibility. Scan J Infect Dis 2004; 36: 24–30.CrossRef Hanberger H, Erlandsson M, Burman LG, Cars O, Gill H, Lindgren S, Lennart N, Olsson-Liljequist B, Walther SM: High antibiotic susceptibility among bacterial pathogens in Swedish ICUs. Report from a nation-wide surveillance program using TA90 as a novel index of susceptibility. Scan J Infect Dis 2004; 36: 24–30.CrossRef
8.
go back to reference Meyer E, Jonas D, Schwab F, Rueden H, Gastmeier P, Daschner FD: Design of a surveillance system of antibiotic use and bacterial resistance in German intensive Care units (SARI). Infection 2003; 31: 208–215.PubMed Meyer E, Jonas D, Schwab F, Rueden H, Gastmeier P, Daschner FD: Design of a surveillance system of antibiotic use and bacterial resistance in German intensive Care units (SARI). Infection 2003; 31: 208–215.PubMed
9.
go back to reference Meyer E, Schwab F, Jonas D, Rueden H, Gastmeier P, Daschner FD: Surveillance of antimicrobial use and antimicrobial resistance in intensive care units (SARI): 1. Antimicrobial use in German intensive care units. Intensive Care Med 2004; 30: 1089–1096.CrossRefPubMed Meyer E, Schwab F, Jonas D, Rueden H, Gastmeier P, Daschner FD: Surveillance of antimicrobial use and antimicrobial resistance in intensive care units (SARI): 1. Antimicrobial use in German intensive care units. Intensive Care Med 2004; 30: 1089–1096.CrossRefPubMed
10.
go back to reference Walther SM, Erlandsson M, Burman LG, Cars O, Gill H, Hoffman M, Isaksson B, Kahlmeter G, Lindgren S, Nilsson L, Olsson-Liljequist B, Hanberger H: Antibiotic prescription practices, consumption and bacterial resistance in a cross section of Swedish intensive care units. Acta Anaesthesiol Scand 2002; 46: 1075–1081.CrossRefPubMed Walther SM, Erlandsson M, Burman LG, Cars O, Gill H, Hoffman M, Isaksson B, Kahlmeter G, Lindgren S, Nilsson L, Olsson-Liljequist B, Hanberger H: Antibiotic prescription practices, consumption and bacterial resistance in a cross section of Swedish intensive care units. Acta Anaesthesiol Scand 2002; 46: 1075–1081.CrossRefPubMed
11.
go back to reference National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32: 470–485. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32: 470–485.
12.
go back to reference Fridkin SK, Steward CD, Edwards JR, Pryor ER, McGowan JE Jr, Archibald LK, Gaynes RP, Tenover FC: Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 1999; 29: 245–252.CrossRefPubMed Fridkin SK, Steward CD, Edwards JR, Pryor ER, McGowan JE Jr, Archibald LK, Gaynes RP, Tenover FC: Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 1999; 29: 245–252.CrossRefPubMed
13.
go back to reference Gastmeier P, Geffers C, Sohr D, Dettenkofer M, Daschner F, Ruden H: Five years working with the German nosocomial infection surveillance system (Krankenhaus Infektions Surveillance System). Am J Infect Control 2003; 31: 316–321.CrossRefPubMed Gastmeier P, Geffers C, Sohr D, Dettenkofer M, Daschner F, Ruden H: Five years working with the German nosocomial infection surveillance system (Krankenhaus Infektions Surveillance System). Am J Infect Control 2003; 31: 316–321.CrossRefPubMed
14.
go back to reference WHO Collaborating centre for Drug Statistics Methodology: Guidelines For ATC Classification and DDDs Assignment. WHO Collaborting Centre, Oslo, Norway, 2004. WHO Collaborating centre for Drug Statistics Methodology: Guidelines For ATC Classification and DDDs Assignment. WHO Collaborting Centre, Oslo, Norway, 2004.
15.
go back to reference DIN 58940-4 Medical microbiology — Methods for the determination of susceptibility of pathogens (except mycobacteria) to antimicrobial agents — part 4: evaluation classes of the minimum inhibitory concentration. Beuth Verlag, Berlin, 1998, pp 1–11. DIN 58940-4 Medical microbiology — Methods for the determination of susceptibility of pathogens (except mycobacteria) to antimicrobial agents — part 4: evaluation classes of the minimum inhibitory concentration. Beuth Verlag, Berlin, 1998, pp 1–11.
16.
go back to reference National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th edn. Approved Standard M7-A4. NCCLS, Wayne, PA, 1997. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th edn. Approved Standard M7-A4. NCCLS, Wayne, PA, 1997.
17.
go back to reference Fridkin SK, Hill HA, Volkova NV, Edwards JR, Lawton RM, Gaynes RP, McGowan JE Jr: Temporal changes in prevalence of antimicrobial resistance in 23 US Hospitals. Emerg Infect Dis 2002; 8: 697–701.PubMed Fridkin SK, Hill HA, Volkova NV, Edwards JR, Lawton RM, Gaynes RP, McGowan JE Jr: Temporal changes in prevalence of antimicrobial resistance in 23 US Hospitals. Emerg Infect Dis 2002; 8: 697–701.PubMed
18.
go back to reference DANMAP 2004: Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, foods and humans in Denmark, 2005, pp 26–31. ISSN 1600-2032. DANMAP 2004: Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, foods and humans in Denmark, 2005, pp 26–31. ISSN 1600-2032.
19.
go back to reference Schwaber MJ, De Medina T, Carmeli Y: Epidemiological interpretation of antibiotic resistance studies — what are we missing? Nat Rev Microbiol 2004; 2: 979–983.CrossRefPubMed Schwaber MJ, De Medina T, Carmeli Y: Epidemiological interpretation of antibiotic resistance studies — what are we missing? Nat Rev Microbiol 2004; 2: 979–983.CrossRefPubMed
20.
go back to reference Cornaglia G, Hryniewicz W, Jarlier V, Kahlmeter G, Mittermayer H, Stratchounski L, Baquero F: European recommendations for antimicrobial resistance surveillance. Clin Microbiol Infect 2004; 10: 349–383.CrossRefPubMed Cornaglia G, Hryniewicz W, Jarlier V, Kahlmeter G, Mittermayer H, Stratchounski L, Baquero F: European recommendations for antimicrobial resistance surveillance. Clin Microbiol Infect 2004; 10: 349–383.CrossRefPubMed
21.
go back to reference Charbonneau P, Parienti JJ, Thibon P, Ramakers M, Daubin C, du Cheyron D, Lebouvier G, Le Coutour X, Leclercq R: Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients: a quasi experimental study. Clin Infect Dis 2006; 42: 778–784.CrossRefPubMed Charbonneau P, Parienti JJ, Thibon P, Ramakers M, Daubin C, du Cheyron D, Lebouvier G, Le Coutour X, Leclercq R: Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients: a quasi experimental study. Clin Infect Dis 2006; 42: 778–784.CrossRefPubMed
22.
go back to reference Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y: Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003; 9: 1415–1422.PubMed Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y: Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003; 9: 1415–1422.PubMed
23.
go back to reference Meyer E, Schwab F, Gastmeier P, Jonas D, Rueden H, Daschner FD: Methicillin-resistant Staphylococcus aureus in German Intensive Care Units during 2000–2003: data from Project SARI (Surveillance of Antimicrobial Use and Antimicrobial Resistance in Intensive Care Units). Infect Control Hosp Epidemiol 2006; 27: 146–154.CrossRefPubMed Meyer E, Schwab F, Gastmeier P, Jonas D, Rueden H, Daschner FD: Methicillin-resistant Staphylococcus aureus in German Intensive Care Units during 2000–2003: data from Project SARI (Surveillance of Antimicrobial Use and Antimicrobial Resistance in Intensive Care Units). Infect Control Hosp Epidemiol 2006; 27: 146–154.CrossRefPubMed
24.
go back to reference Meyer E, Schwab F, Jonas D, Ruden H, Gastmeier P, Daschner FD: Temporal changes in bacterial resistance in German intensive care units, 2001–2003: data from the SARI (surveillance of antimicrobial use and antimicrobial resistance in intensive care units) project. J Hosp Infect 2005; 60: 348–352.CrossRefPubMed Meyer E, Schwab F, Jonas D, Ruden H, Gastmeier P, Daschner FD: Temporal changes in bacterial resistance in German intensive care units, 2001–2003: data from the SARI (surveillance of antimicrobial use and antimicrobial resistance in intensive care units) project. J Hosp Infect 2005; 60: 348–352.CrossRefPubMed
25.
go back to reference Robert-Koch Institute: On the emergence and spread of glycopeptide resistant enterococci. Epidemiol Bull 2005; 17/2005: 149–155. Robert-Koch Institute: On the emergence and spread of glycopeptide resistant enterococci. Epidemiol Bull 2005; 17/2005: 149–155.
26.
go back to reference MacDougall C, Powell JP, Johnson CK, Edmond MB, Polk RE: Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 2005; 41: 435–440.CrossRefPubMed MacDougall C, Powell JP, Johnson CK, Edmond MB, Polk RE: Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 2005; 41: 435–440.CrossRefPubMed
27.
go back to reference Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, Wenzel RP: Emerging resistance among bacterial pathogens in the intensive care unit — a European and North American Surveillance study (2000–2002). Ann Clin Microbiol Antimicrob 2004; 3: 1–11.CrossRefPubMed Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, Wenzel RP: Emerging resistance among bacterial pathogens in the intensive care unit — a European and North American Surveillance study (2000–2002). Ann Clin Microbiol Antimicrob 2004; 3: 1–11.CrossRefPubMed
Metadata
Title
Surveillance of Antimicrobial Use and Antimicrobial Resistance in German Intensive Care Units (SARI): A Summary of the Data from 2001 through 2004
Authors
E. Meyer
F. Schwab
P. Gastmeier
H. Rueden
F. D. Daschner
Publication date
01-12-2006
Publisher
Urban & Vogel
Published in
Infection / Issue 6/2006
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-006-6619-x

Other articles of this Issue 6/2006

Infection 6/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.